CN201342183Y - Embedded rechargeable intracavity sustained-release dosing pump - Google Patents
Embedded rechargeable intracavity sustained-release dosing pump Download PDFInfo
- Publication number
- CN201342183Y CN201342183Y CNU2008201578748U CN200820157874U CN201342183Y CN 201342183 Y CN201342183 Y CN 201342183Y CN U2008201578748 U CNU2008201578748 U CN U2008201578748U CN 200820157874 U CN200820157874 U CN 200820157874U CN 201342183 Y CN201342183 Y CN 201342183Y
- Authority
- CN
- China
- Prior art keywords
- sustained
- pump
- pump housing
- inner chamber
- elastic force
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 23
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 25
- 238000007789 sealing Methods 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract 3
- 238000009958 sewing Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000000956 alloy Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The utility model relates to an embedded rechargeable sustained-release dosing pump, which comprises a pump body, a flexible puncturing membrane, an inner duct, a guide valve, an outer duct and a fixer. The dosing pump is characterized in that the pump body and the flexible puncturing membrane are embedded and stuck by a fixed sealing ring to form an inner cavity; the flexible puncturing membrane can bounce up after liquid medicine is injected to enlarge the volume of the inner chamber to 5-30ml for holding the liquid medicine of the corresponding volume; a fixing hole for sewing and fixing the pump body under the human skin is formed on the pump body; the outer duct is used for connecting a human blood vessel, the connection between the outer duct and the blood vessel is fixed by the fixer; in addition, the inner cavity and the outer duct are communicated with each other through the inner duct; and the guide valve is arranged on the inner duct and adjusted to control the flow speed of the liquid medicine in the inner cavity flowing into the blood vessel from the outer duct. The pump structure has the advantages of simple structure, low cost, safety and reliability, and the liquid medicine can be repeatedly filled through the skin.
Description
Technical field
This utility model relates to a kind of medical treatment device that is used for sustained-release administration, belongs to medical apparatus and instruments, and particularly, it relates to a kind of filled intracavity type sustained-release administration pump that connects blood vessel in the human body that is embedded in.
Background technology
In existing medical procedure, some disease (as, malignant tumor, endocrinopathy etc.) need usually for a long time through tremulous pulse or vein blood vessel drug administration by injection, the patient must be every other day in addition every day hospital or medical institutions' injectable drug for several times, bring great inconvenience for patient's work, life, the injection site also may produce untoward reaction such as scleroma, ulceration owing to prolonged and repeated injection; In addition, some medicine since in vivo the half-life short, intermittently heavy dose of administration is difficult to continue in vivo to keep onset concentration, and the toxic and side effects of medicine also can increase because the dosage of administration at intermittence is excessive, brings very big misery to the patient.Therefore, need a kind of doser that can be embedded in connection blood vessel in the human body of exploitation, in order to continue the discharging effective dose of medicine thing lentamente in vivo, and as possible, also wish to repeat to charge into medicine, thereby can use repeatedly, the saving cost also reduces the patient and repeats embedding misery.
Summary of the invention
Problem to be solved in the utility model is to overcome the deficiencies in the prior art, provides to be embedded in the subcutaneous administration pump that can continue to discharge lentamente the effective dose of medicine thing in vivo of human body.Particularly, the purpose of this utility model is to provide a kind of sustained-release administration pump that the body embedded set connects blood vessel that is used for, when charging into medicine, pierce through the elastic force puncture film that is embedded on this subcutaneous pump housing with the injection needle percutaneous, injecting liquid drug is arrived in the pump housing inner chamber, elastic force puncture film passive raising up of meeting in intracavity medicine stowing operation, produce certain resilient pressure during elastic force puncture film projection, pump housing intracavity medicine is pumped to inner catheter and outer catheter direction, scalable diaphragm valve on the inner catheter matches with elastic force puncture film, control medicine stream is slowly at the uniform velocity to subcutaneous infiltration, by regulate diaphragm valve make certain volume in the pump housing (as, medicinal liquid 15ml) slowly pumped in a couple of days to several weeks, thereby satisfied the treatment needs of clinical various disease.This sustained-release administration pump good biocompatibility does not have toxic and side effects and anaphylaxis; Have the design of excellent drug antiseep, safe and reliable; By this device can be implemented in the human body automatically, the administering mode of slow release, medicine continues medication through slow release, more meets pharmacokinetics and Human Physiology needs, can reduce the toxic and side effects of chemotherapeutic etc., the raising curative effect.This sustained-release administration pump can be used for the administration of the medicine of the chemotherapy (as 5-fluorouracil etc.) of prevention of recurrence behind cancer chemotherapy and the tumor resection, biological immune treatment (as interferon, thymosin etc.), the ache in late cancer pain management of tumour patient (as the morphine class etc.), endocrinopathy hormone replacement therapy numerous areas such as (as insulin, estrogen), has broad application prospects.
The purpose of this utility model comes to be realized by the following technical programs.Particularly, this utility model provides a kind of sustained-release administration pump that the body embedded set connects blood vessel that is used for, it comprises the pump housing 2, elastic force puncture film 5, inner catheter 6, diaphragm valve 7, outer catheter 10 and holder 9, it is characterized in that, the pump housing 2 is pressed or is adhered to by embedding by fixed seal ring 4 with elastic force puncture film 5 and forms an inner chamber 3, this elastic force puncture film 5 can be upspring after injecting medicinal liquid, makes inner chamber 3 expand the 5-30ml volume to and holds the medicinal liquid of respective volume; Be useful on the pump housing 2 pump housing sutured in the subcutaneous fixing hole 1 of human body; Outer catheter 10 is used to connect human vas, and outer catheter 10 is fixing with holder 9 with the junction of blood vessel; And, be connected by inner catheter 6 between inner chamber 3 and the outer catheter 10, have diaphragm valve 7 on the inner catheter 6, control the flow velocity that medicinal liquid in the inner chamber 3 flows out outer catheter 10 intravasations by regulating diaphragm valve 7.It is subcutaneous that this sustained-release administration pump is embedded into human body when can not inject medicinal liquid, with the fixing junction of outer catheter 9 and blood vessel of holder 9, prevents to go out blood vessel from outer catheter 9 effusive fluid seepages, can alleviate the misery of the process of inserting to the patient like this; Be embedded into human body subcutaneous after, can medicinal liquid be injected inner chamber 3 by syringe.When not injecting medicinal liquid, inner chamber 3 volumes are less than 15ml, and preferable volume is 0ml; By the injection of medicinal liquid, elastic force puncture film 5 is upspring, during as injection medicinal liquid 15ml, hold this medicinal liquid just can make inner chamber 3 expand the 15ml volume to.According to the use amount of conventional medicinal liquid, in above-mentioned sustained-release administration pump, elastic force puncture film 5 can be upspring after injecting medicinal liquid, makes inner chamber 3 expand the 15ml volume to and holds the medicinal liquid of 15ml.
Preferably in above-mentioned sustained-release administration pump, the chamber pressure that the resilience force that elastic force puncture film 5 relies on self-deformations to produce causes between 10-100Pa, and repeatedly after flexible 200 times resilience force descend and be no more than 2Pa.Under the effect of the resilience force that elastic force puncture film 5 self-deformations produce,, can realize administering mode automatic, slow, that continue like this, make medicinal liquid pump from the blood vessel of outer catheter 10 outside pump through inner catheter 6 at last by regulating the pod apertures 8 on the diaphragm valve 7.
Preferably in above-mentioned sustained-release administration pump, be useful on the pump housing 2 pump housing 2 sutured in 4 subcutaneous fixing holes 1 of human body.So preferred fixing hole 1 quantity is convenient to being embedded in human body securely subcutaneous.
Preferably in above-mentioned sustained-release administration pump, the medicinal liquid flow velocity of diaphragm valve 7 controls is between 0.5ml/ hour to 0.01ml/ hour.Like this, just may command 15ml dose slowly at the uniform velocity pumped to 1 week at 1 day, met the demand of real administration.
Above-mentioned sustained-release administration pump can use conventional material to make, and can buy by market.For example, insert the material of human body makes with tissue contact portion being used to of using that those skilled in the art used always, material therefor is biocompatible polymer material or biological alloy, can there be repulsion with tissue like this, for example the pump housing 2 can be with medical polysulfones manufacturing, outer catheter 10 can be used the biocompatible alloy manufacturing, and elastic force puncture film 5 is preferably used the silicone rubber manufacturing, and it is non-leakage to make elastic force puncture film can tolerate thousands of inferior punctures like this.
The sustained-release administration pump that the body embedded set that this utility model provides connects blood vessel has following multiple beneficial effect: 1, can place subcutaneous for a long time, pump housing sutured and puncture location are easily, pump housing sealing, histocompatibility are good, medicinal liquid does not have the dystopy seepage, and is safe and reliable, so patient need not to be in hospital during the administration, but orthobiosis, work, thereby greatly improve quality of life of patient; 2, can be after this device implants repeatedly through subcutaneous dabbling drug, treatment can be finished in outpatient service, and doctor and patient can be according to laying one's hand on and subcutaneous pump housing surface elastic force film shape is learnt pump housing giving drugs into nose quantitative changeization, promptly point out medicine to use up as recover depression fully from the protuberance state, can load medicine again, so expense is cheap, easy to operate; 3, this pump configuration is simple, low cost of manufacture.
Description of drawings
Fig. 1 is the structural representation that is used for the sustained-release administration pump of body embedded set connection blood vessel of the present utility model, has shown each parts and the annexation of this sustained-release administration pump.Wherein, the relation of Reference numeral and parts is as follows: 1. fixing hole; 2. the pump housing; 3. inner chamber; 4. fixed seal ring; 5. elastic force puncture film; 6. inner catheter; 7. diaphragm valve; 8. pod apertures; 9. holder; 10. outer catheter.
The specific embodiment
Below in conjunction with accompanying drawing formation of the present utility model is further described:
Instantiation and accompanying drawing are illustrated sustained-release administration pump of the present utility model.Yet, should be understood that the instantiation that provides only is in order to illustrate that obviously those of ordinary skill in the art can make various corrections and change to the present invention within the scope of the invention according to detailed description.
Claims (4)
1. one kind is used for the sustained-release administration pump that the body embedded set connects blood vessel, it comprises the pump housing (2), elastic force puncture film (5), inner catheter (6), diaphragm valve (7), outer catheter (10) and holder (9), it is characterized in that, the pump housing (2) is pressed or is adhered to by embedding by fixed seal ring (4) with elastic force puncture film (5) and forms an inner chamber (3), this elastic force puncture film (5) can be upspring after injecting medicinal liquid, makes inner chamber (3) expand the 5-30ml volume to and holds the medicinal liquid of respective volume; Be useful on pump housing sutured on the pump housing (2) in the subcutaneous fixing hole of human body (1); Outer catheter (10) is used to connect human vas, and outer catheter (10) is fixing with holder (9) with the junction of blood vessel; And, be connected by inner catheter (6) between inner chamber (3) and the outer catheter (10), have diaphragm valve (7) on the inner catheter (6), control the flow velocity that medicinal liquid in the inner chamber (3) flows out outer catheter (10) intravasation by regulating diaphragm valve (7).
2. sustained-release administration pump according to claim 1 is characterized in that, the chamber pressure of elastic force puncture film (5) is between 10-100Pa.
3. sustained-release administration pump according to claim 1 is characterized in that, is useful on the pump housing (2) pump housing sutured in subcutaneous 4 fixing holes (1) of human body.
4. sustained-release administration pump according to claim 1 is characterized in that, the expansion volume of inner chamber (3) is 15ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008201578748U CN201342183Y (en) | 2008-12-25 | 2008-12-25 | Embedded rechargeable intracavity sustained-release dosing pump |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008201578748U CN201342183Y (en) | 2008-12-25 | 2008-12-25 | Embedded rechargeable intracavity sustained-release dosing pump |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201342183Y true CN201342183Y (en) | 2009-11-11 |
Family
ID=41273768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2008201578748U Expired - Fee Related CN201342183Y (en) | 2008-12-25 | 2008-12-25 | Embedded rechargeable intracavity sustained-release dosing pump |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201342183Y (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110841134A (en) * | 2018-08-20 | 2020-02-28 | 张海军 | Automatic drug delivery system for treating Parkinson's disease |
| CN111330137A (en) * | 2018-12-17 | 2020-06-26 | 深圳市擎源医疗器械有限公司 | Drug delivery device |
-
2008
- 2008-12-25 CN CNU2008201578748U patent/CN201342183Y/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110841134A (en) * | 2018-08-20 | 2020-02-28 | 张海军 | Automatic drug delivery system for treating Parkinson's disease |
| CN111330137A (en) * | 2018-12-17 | 2020-06-26 | 深圳市擎源医疗器械有限公司 | Drug delivery device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sefton | Implantable pumps | |
| US8430847B2 (en) | Infusion pump system | |
| US6699218B2 (en) | Transcutaneous delivery means | |
| US4464178A (en) | Method and apparatus for administration of fluids | |
| US7018360B2 (en) | Flow restriction system and method for patient infusion device | |
| US20040092865A1 (en) | Transcutaneous delivery means | |
| US20060282290A1 (en) | Components and Methods For Patient Infusion Device | |
| US20150057615A1 (en) | Infusion Pump System | |
| JP2016168411A (en) | Nighttime basal dosing device | |
| JP2020163204A (en) | Rapid administration | |
| AU2010207762A1 (en) | Transcutaneous delivery means | |
| CN201342183Y (en) | Embedded rechargeable intracavity sustained-release dosing pump | |
| CN101502695B (en) | Embedded type chargeable sustained-release administration pump | |
| CN102151346A (en) | Hypodermic implantation type medicine feeder | |
| CN201324434Y (en) | Embedded refilling hypodermic slow release dosing pump | |
| CN102488958A (en) | Implanted chemical therapy device for abdominal cavity | |
| CN202061177U (en) | Hypodermic implantation type drug administration device | |
| CN201200664Y (en) | Novel two-chamber medicament sustained-release infusion device | |
| CN205235169U (en) | Disposable two -chamber silica gel catheter connects | |
| KR20230109262A (en) | Chamber unit for subcutaneous injection with drug storage and discharge function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091111 Termination date: 20141225 |
|
| EXPY | Termination of patent right or utility model |